Halozyme Therapeutics, Inc. (HALO)
(Delayed Data from NSDQ)
$40.91 USD
+0.50 (1.24%)
Updated Mar 5, 2021 04:00 PM ET
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank | Definition | Annualized Return |
---|---|---|
1 | Strong Buy | 24.41% |
2 | Buy | 17.88% |
3 | Hold | 9.48% |
4 | Sell | 5.03% |
5 | Strong Sell | 1.87% |
S&P | 500 | 10.70% |
Zacks Rank Education - Learn about the Zacks Rank
Zacks Rank Home - Zacks Rank resources in one place
Zacks Premium - The only way to fully access the Zacks Rank
3-Hold of 5 3
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.
Value Score | A |
---|---|
Growth Score | A |
Momentum Score | A |
VGM Score | A |
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Zacks Style Scores Education - Learn more about the Zacks Style Scores
D Value B Growth D Momentum C VGM
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.
Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank
Zacks News
Halozyme (HALO) Q4 Earnings Miss, 2021 View Weak, Stock Falls
by Zacks Equity Research
Halozyme (HALO) reports lower-than-expected fourth-quarter earnings. However, revenues beat estimates. The company's outlook for 2021 is below market expectations.
JNJPositive Net Change RHHBYPositive Net Change HALOPositive Net Change HZNPPositive Net Change
biotechs earnings
Drug/Biotech Stock Q4 Earnings on Feb 23: JAZZ, ARNA & More
by Kinjel Shah
Let us take a look at five small biotech companies, JAZZ, ARNA, HALO, EPZM, ESPR, which are gearing up for their earnings release.
ARNAPositive Net Change JAZZPositive Net Change HALOPositive Net Change ESPRPositive Net Change EPZMPositive Net Change
biotechs
UnitedHealth (UNH) Q4 Earnings Top Estimates, Revenues up Y/Y
by Zacks Equity Research
UnitedHealth's (UNH) fourth-quarter results benefit from higher revenues and return of healthcare utilization to normalcy level, partly offset by higher costs.
UNHPositive Net Change THCPositive Net Change HALOPositive Net Change TDOCNegative Net Change
earnings medical
Precision BioSciences' (DTIL) New Lymphoma Drug IND Gets FDA Nod
by Zacks Equity Research
The FDA accepts Precision BioSciences' (DTIL) regulatory application to initiate a clinical study on its next-generation CD19 product candidate, PBCAR19B.
GILDPositive Net Change LLYPositive Net Change HALOPositive Net Change DTILPositive Net Change
biotechs
J&J's (JNJ) Darzalex Faspro Gets FDA Nod for Amyloidosis
by Zacks Equity Research
J&J (JNJ) gets accelerated approval for a new indication of Darzalex Faspro in combination with bortezomib, cyclophosphamide and dexamethasone for treating amyloidosis patients.
JNJPositive Net Change CELGPositive Net Change HALOPositive Net Change GMABPositive Net Change
pharmaceuticals
Novartis' (NVS) Ligelizumab Gets Breakthrough Therapy Status
by Zacks Equity Research
Novartis (NVS) gets Breakthrough Therapy designation by the FDA for ligelizumab for the treatment of chronic spontaneous urticaria.
ALKSPositive Net Change RHHBYPositive Net Change NVSPositive Net Change HALOPositive Net Change
pharmaceuticals
Lexicon (LXRX) Soars on FDA Permission for Sotagliflozin NDA
by Zacks Equity Research
Lexicon (LXRX) announces that data from two late-stage studies on its type II diabetes candidate, sotagliflozin, can support a regulatory approval application.
SNYPositive Net Change BMYPositive Net Change HALOPositive Net Change LXRXPositive Net Change
biotechs
Acorda (ACOR) Soars on Sale of Manufacturing Unit for Inbrija
by Zacks Equity Research
Acorda (ACOR) inks an agreement to sell its Inbrija manufacturing operations in Chelsea for $80 million to Catalent. The company also announces a corporate restructuring plan to save costs. Shares up.
ACORNegative Net Change HALOPositive Net Change CTLTPositive Net Change BPMCPositive Net Change
biotechs
Marinus (MRNS) Gets Positive FDA Response for Ganaxolone Study
by Zacks Equity Research
Marinus (MRNS) gets positive FDA response for phase III Marigold study on oral ganaxolone in children and young adults with CDKL5 deficiency disorder that appears sufficient to support the NDA filing.
ALKSPositive Net Change HALOPositive Net Change MRNSPositive Net Change ARPONegative Net Change
pharmaceuticals
Regeneron (REGN), U.S. Government Ink Deal for COVID-19 Treatment
by Zacks Equity Research
Regeneron (REGN) inks deal with the U.S. government to sell additional 1.25 million doses (an agreement value of up to $2.625 billion) of its COVID-19 antibody cocktail.
ALKSPositive Net Change REGNPositive Net Change RHHBYPositive Net Change HALOPositive Net Change
biotechs
AbbVie (ABBV) Inks Deal to Acquire Medical Device Company
by Zacks Equity Research
AbbVie (ABBV) signs an agreement to acquire privately held Cypris Medical, including the latter's Xact device which is used for performing face and neck lifts.
ALXNPositive Net Change HALOPositive Net Change ABBVPositive Net Change RARENegative Net Change
pharmaceuticals
3 Biotech Stocks Poised to Outperform Amid Coronavirus Pandemic
by Ekta Bagri
The focus on coronavirus treatments should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position NVAX, HALO and BPMC to outperform.
NVAXPositive Net Change BIIBPositive Net Change REGNPositive Net Change GILDPositive Net Change VRTXPositive Net Change HALOPositive Net Change BPMCPositive Net Change
biotechs
Editas (EDIT) Gets FDA Nod to Begin Safety Study on EDIT-301
by Zacks Equity Research
The FDA clears the initiation of the safety phase of Editas' (EDIT) early-stage study on investigational gene-editing therapy EDIT-301 for treating sickle cell disease. Shares down.
HALOPositive Net Change EDITPositive Net Change NTLANegative Net Change CRSPNegative Net Change
biotechs
bluebird (BLUE) to Spin Off Oncology Unit Into Separate Entity
by Zacks Equity Research
bluebird (BLUE) to separate its severe genetic disease and oncology businesses into different and independent publicly traded companies. Shares up.
BMYPositive Net Change HALOPositive Net Change BLUEPositive Net Change RCUSPositive Net Change
biotechs
Horizon (HZNP) Provides Preliminary 2020 Financial Results
by Zacks Equity Research
Horizon (HZNP) provides 2020 preliminary financial results and updates on its key drugs.
ALKSPositive Net Change HALOPositive Net Change HZNPPositive Net Change ARPONegative Net Change
biotechs
Ultragenyx (RARE) Presents Preliminary 2020 Revenues & Guidance
by Zacks Equity Research
Ultragenyx (RARE) provides preliminary 2020 Crysvita revenues and 2021 revenue guidance for the same.
ALKSPositive Net Change HALOPositive Net Change RARENegative Net Change ARPONegative Net Change
biotechs
Sarepta (SRPT) Looks Good: Stock Adds 9.1% in Session
by Zacks Equity Research
Sarepta (SRPT) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
HALOPositive Net Change SRPTPositive Net Change
biotechs
Infrastructure and Energy Alternatives, Carrols Restaurant, Moderna, Blueprint Medicines and Halozyme Therapeutics highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Infrastructure and Energy Alternatives, Carrols Restaurant, Moderna, Blueprint Medicines and Halozyme Therapeutics highlighted as Zacks Bull and Bear of the Day
MRNANegative Net Change HALOPositive Net Change TASTPositive Net Change BPMCPositive Net Change IEANegative Net Change
energy medical restaurants
Merus (MRUS) Stock Up on FDA's Fast Track Tag for Zenocutuzumab
by Zacks Equity Research
The FDA bestows a Fast Track status to Merus' (MRUS) lead pipeline candidate, Zenocutuzumab, for treating metastatic solid tumors harboring NRG1 gene fusions. Shares rise.
ALKSPositive Net Change INCYPositive Net Change HALOPositive Net Change MRUSPositive Net Change
biotechs
Alnylam (ALNY) Posts Positive Top-Line Data From Vutrisiran Study
by Zacks Equity Research
Alnylam (ALNY) reports positive top-line results from the phase III -HELIOS-A study of vutrisiran in development for the treatment of transthyretin-mediated amyloidosis with polyneuropathy.
ALKSPositive Net Change ALNYPositive Net Change HALOPositive Net Change ASLNPositive Net Change
biotechs
3 Biotech Stocks Worth Adding to Your Portfolio in 2021
by Ekta Bagri
We highlight a few biotech companies, which outperformed the sector in 2020 and are likely to witness a winning run in the near term.
REGNPositive Net Change MRNANegative Net Change NVAXPositive Net Change HALOPositive Net Change BPMCPositive Net Change
biotechs pharmaceuticals
Catayst (CPRX) Provides Long-Term Portfolio Expansion Plans
by Zacks Equity Research
Catalyst (CPRX) plans to expand its product portfolio beyond Firdapse.
ALKSPositive Net Change HALOPositive Net Change CPRXPositive Net Change ASLNPositive Net Change
pharmaceuticals
REGENXBIO (RGNX) Provides Update on RGX-314 & Begins New Program
by Zacks Equity Research
REGENXBIO (RGNX) provided an update on the RGX-314 programs. Further, the company made an announcement of a new program, RGX-202, for the treatment of Duchenne Muscular Dystrophy
ALKSPositive Net Change HALOPositive Net Change RGNXPositive Net Change ASLNPositive Net Change
biotechs
Calithera (CALA) Plunges as CANTANA Study on Telaglenastat Fails
by Zacks Equity Research
Calithera (CALA) tanks as CANTATA study on its lead pipeline candidate, telaglenastat, did not achieve its primary goal for RCC.
MRKPositive Net Change EXELPositive Net Change HALOPositive Net Change CALAPositive Net Change
biotechs pharmaceuticals
Generation Bio (GBIO) Catches Eye: Stock Jumps 6.1%
by Zacks Equity Research
Generation Bio (GBIO) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
HALOPositive Net Change GBIONegative Net Change
medical